TIAA CREF Investment Management LLC raised its holdings in Veracyte, Inc. (NASDAQ:VCYT) by 46.0% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 93,358 shares of the biotechnology company’s stock after purchasing an additional 29,406 shares during the quarter. TIAA CREF Investment Management LLC owned 0.28% of Veracyte worth $778,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also made changes to their positions in VCYT. Wells Fargo & Company MN grew its stake in Veracyte by 112.8% in the 1st quarter. Wells Fargo & Company MN now owns 18,752 shares of the biotechnology company’s stock valued at $172,000 after purchasing an additional 9,938 shares during the period. Bank of New York Mellon Corp grew its stake in Veracyte by 3.0% in the 1st quarter. Bank of New York Mellon Corp now owns 61,312 shares of the biotechnology company’s stock valued at $563,000 after purchasing an additional 1,795 shares during the period. Parametric Portfolio Associates LLC grew its stake in Veracyte by 39.5% in the 1st quarter. Parametric Portfolio Associates LLC now owns 81,145 shares of the biotechnology company’s stock valued at $745,000 after purchasing an additional 22,966 shares during the period. JPMorgan Chase & Co. grew its stake in Veracyte by 111.1% in the 1st quarter. JPMorgan Chase & Co. now owns 49,765 shares of the biotechnology company’s stock valued at $456,000 after purchasing an additional 26,186 shares during the period. Finally, Vanguard Group Inc. grew its stake in Veracyte by 4.4% in the 1st quarter. Vanguard Group Inc. now owns 825,860 shares of the biotechnology company’s stock valued at $7,581,000 after purchasing an additional 34,966 shares during the period. Hedge funds and other institutional investors own 66.32% of the company’s stock.

Veracyte, Inc. (VCYT) opened at $6.13 on Tuesday. Veracyte, Inc. has a 1 year low of $5.75 and a 1 year high of $9.80. The company has a current ratio of 5.19, a quick ratio of 4.86 and a debt-to-equity ratio of 0.59.

Veracyte (NASDAQ:VCYT) last issued its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.21) EPS for the quarter, meeting analysts’ consensus estimates of ($0.21). Veracyte had a negative return on equity of 52.99% and a negative net margin of 38.19%. The firm had revenue of $17.50 million for the quarter, compared to analysts’ expectations of $19.54 million. During the same quarter in the prior year, the firm earned ($0.20) EPS. The business’s revenue for the quarter was down 5.9% compared to the same quarter last year. equities research analysts anticipate that Veracyte, Inc. will post -0.85 earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Veracyte, Inc. (VCYT) Holdings Lifted by TIAA CREF Investment Management LLC” was first published by Daily Political and is owned by of Daily Political. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/11/14/veracyte-inc-vcyt-holdings-lifted-by-tiaa-cref-investment-management-llc.html.

In related news, Director Evan/ Fa Jones sold 20,000 shares of the stock in a transaction dated Wednesday, August 23rd. The stock was sold at an average price of $7.92, for a total transaction of $158,400.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Bonnie H. Anderson sold 6,000 shares of the stock in a transaction dated Wednesday, October 18th. The stock was sold at an average price of $9.09, for a total value of $54,540.00. Following the sale, the chief executive officer now directly owns 16,000 shares in the company, valued at approximately $145,440. The disclosure for this sale can be found here. Insiders have sold a total of 130,500 shares of company stock worth $1,085,065 in the last ninety days. Insiders own 13.40% of the company’s stock.

VCYT has been the subject of a number of recent analyst reports. Zacks Investment Research downgraded Veracyte from a “hold” rating to a “sell” rating in a research note on Thursday, October 12th. BidaskClub downgraded Veracyte from a “sell” rating to a “strong sell” rating in a research note on Wednesday, July 19th. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Veracyte in a research report on Tuesday, September 12th. BTIG Research reaffirmed a “buy” rating and set a $13.00 price target on shares of Veracyte in a research report on Thursday, August 31st. Finally, ValuEngine cut Veracyte from a “hold” rating to a “sell” rating in a research report on Tuesday, September 12th. One research analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $11.85.

Veracyte Company Profile

Veracyte, Inc is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis.

Institutional Ownership by Quarter for Veracyte (NASDAQ:VCYT)

Receive News & Ratings for Veracyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.